Mangalam Drugs Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Mangalam Drugs Q2 results FY27 announcement is the next scheduled earnings event for Mangalam Drugs and Organics Ltd., a maker of active pharmaceutical ingredients and intermediates, with a focus on anti-malarial and anti-infective molecules, operating plants in Gujarat and Maharashtra. The stock traded at Rs 34.00 on the NSE on 11 September 2026, up 1.22% from the previous close of Rs 33.59, about 35.1% below its 52-week high of Rs 52.40 and 30.5% above its 52-week low of Rs 26.05.

What makes the Mangalam Drugs Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 49.54 crore of revenue and a loss of Rs 7.35 crore, while the most recent quarter on record, Q1 FY27, produced Rs 57.12 crore and a loss of Rs 7.64 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the Mangalam Drugs Q2 Results FY27 Date?

The Mangalam Drugs Q2 results date for FY27 is not confirmed. As of 11 September 2026, Mangalam Drugs and Organics Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Mangalam Drugs Q2 results date becomes public through that filing rather than through any advance announcement.

The Mangalam Drugs Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Mangalam Drugs and Organics.

Mangalam Drugs Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the Mangalam Drugs Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Mangalam Drugs and Organics. The Mangalam Drugs Q2 results watchlist below is built from what the company has actually reported and disclosed.

The first is revenue, which was Rs 49.54 crore in September 2025, the weakest of the five quarters, against Rs 57.12 crore in Q1 FY27. Sales have not recovered to the Rs 72.78 crore of March 2025 or the Rs 88.71 crore of December 2024.

The second is the operating margin, which was negative 5.73% in September 2025 and positive 1.59% in Q1 FY27. Four of the five quarters here are operating losses, and June 2026 is the first positive operating quarter since March 2025.

The third is whether the net loss narrows further. All five quarters are loss-making at the net level, from Rs 7.35 crore to Rs 13.80 crore, and the June 2026 loss of Rs 7.64 crore is the second smallest of the set.

Check Mangalam Drugs and Organics Ltd. Live Fundamentals on the Univest Screener

Mangalam Drugs Q2 Results Preview: The Q1 FY27 Actuals It Builds On

Mangalam Drugs and Organics Ltd. reported revenue of Rs 57.12 crore in Q1 FY27, down 0.16% from Rs 57.21 crore in Q1 FY26, and a loss of Rs 7.64 crore at the net level, a narrower loss than the Rs 13.80 crore loss of Q1 FY26. These are reported actuals, not estimates.

Sequentially, revenue was down 15.11% over the March 2026 quarter figure of Rs 67.29 crore, and net profit was a narrower loss than the Rs 13.42 crore loss of Q4 FY26. Operating margin stood at 1.59% in Q1 FY27 against negative 5.73% in the September 2025 quarter, which is the comparison the Mangalam Drugs Q2 results print will be read against.

Q2 FY26 Base: The Comparison Mangalam Drugs Q2 Results FY27 Must Beat

Mangalam Drugs and Organics Ltd. reported revenue of Rs 49.54 crore and a loss of Rs 7.35 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Mangalam Drugs Q2 results preview.

Because the base quarter itself was loss-making, a year-on-year percentage comparison of profit is not meaningful for Mangalam Drugs and Organics. The more useful test in the Mangalam Drugs Q2 results print is whether the company reports a profit at all, and how the income line of Rs 49.54 crore compares with the Rs 57.12 crore of the June 2026 quarter.

Mangalam Drugs and Organics Quarterly Results Trend Over the Last Four Quarters

Quarter	Revenue (Rs Cr)	Net Profit (Rs Cr)
Q2 FY26 (Sep 2025)	49.54	(7.35)
Q3 FY26 (Dec 2025)	58.38	(9.84)
Q4 FY26 (Mar 2026)	67.29	(13.42)
Q1 FY27 (Jun 2026)	57.12	(7.64)

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company's exchange filings, and they are the only basis this Mangalam Drugs Q2 results preview uses.

Revenue across those four quarters ranged from Rs 49.54 crore to Rs 67.29 crore, and net profit from Rs 13.42 crore loss to Rs 7.35 crore loss. That spread is the honest context for the Mangalam Drugs Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape Mangalam Drugs Q2 Results FY27

The Mangalam Drugs Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Mangalam Drugs and Organics has already reported.

The Margin Broke a Year Ago

Operating margin was 13.60% in March 2025 and 9.89% in December 2024, then turned negative at the start of this window. The five-quarter series therefore sits entirely inside a downturn and is not comparable with the prior year.

Interest Is Not Covered by Operations

Interest of about Rs 15.8 crore across the window sits against cumulative operating profit of negative Rs 13.7 crore, and depreciation alone exceeds operating profit in every quarter. The company's filings disclose defaults on bank loans of Rs 951.19 lakh and Rs 606.08 lakh since October 2025.

Reserves Are Being Eroded

Reserves fell from Rs 133 crore to Rs 87 crore over the last year while borrowings rose from Rs 96 crore to Rs 105 crore. Net worth remains positive and the stock trades at 0.52 times a book value of Rs 65.10, with no price to earnings ratio shown on trailing losses.

Mangalam Drugs Q2 Results FY27: Share Price and Valuation Going Into the Print

Mangalam Drugs and Organics share price today is Rs 34.00 on the NSE, up Rs 0.41 or 1.22% from the previous close of Rs 33.59 on 11 September 2026, ahead of the Mangalam Drugs Q2 results announcement.

Metric	Value (11 September 2026)
NSE Symbol	MANGALAM
Current Market Price	Rs 34.00
52-Week High	Rs 52.40
52-Week Low	Rs 26.05
Market Capitalisation	Rs 54 crore
PE Ratio	Not meaningful on a trailing loss
PB Ratio	0.52
EPS (TTM)	Not meaningful on a trailing loss
Book Value per Share	Rs 65.10
Debt to Equity	1.02
Return on Equity	-35.2%
50-Day Moving Average	Rs 28.59
200-Day Moving Average	Rs 30.38
RSI (14)	62.65

The stock trades above both its 50-day average of Rs 28.59 and its 200-day average of Rs 30.38, with a 14-day RSI of 62.65. None of this is a view on where the shares go once the Mangalam Drugs Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track Mangalam Drugs and Organics Ltd. live price and quarterly earnings updates.

What Investors Should Watch When Mangalam Drugs Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the Mangalam Drugs Q2 results print in proportion.

1. Revenue against the Rs 49.54 crore reported in the September 2025 base quarter
2. Net profit against a loss of Rs 7.35 crore in that same quarter
3. Operating margin against 1.59% in Q1 FY27
4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Mangalam Drugs Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on Mangalam Drugs Q2 Results FY27

The Mangalam Drugs Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Mangalam Drugs and Organics Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the Mangalam Drugs Q2 results FY27 print faces a base of Rs 49.54 crore in revenue and a loss of Rs 7.35 crore, with the most recent quarter having delivered Rs 57.12 crore and a loss of Rs 7.64 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Mangalam Drugs and Organics, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

FAQs on Mangalam Drugs Q2 Results FY27

What is the Mangalam Drugs Q2 results date for FY27?

Ans. The Mangalam Drugs Q2 results date for FY27 is not confirmed. Mangalam Drugs and Organics Ltd. had not filed a board meeting intimation with the NSE or BSE as of 11 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the Mangalam Drugs Q2 results 2026 cover?

Ans. The Mangalam Drugs Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Mangalam Drugs and Organics Ltd. reports revenue, operating profit and net profit for that period, and the Mangalam Drugs Q2 results filing also carries the notes to the accounts.

What were the Mangalam Drugs and Organics Q1 FY27 results?

Ans. Mangalam Drugs and Organics Ltd. reported revenue of Rs 57.12 crore in Q1 FY27 and a loss of Rs 7.64 crore at the net level. Revenue was down 0.16% versus Q1 FY26 and net profit was a narrower loss than the Rs 13.80 crore loss of Q1 FY26.

What were Mangalam Drugs and Organics Q2 FY26 results in the September 2025 quarter?

Ans. Mangalam Drugs and Organics Ltd. reported revenue of Rs 49.54 crore and a loss of Rs 7.35 crore in Q2 FY26. Operating margin was negative 5.73%. Those figures form the base for the Mangalam Drugs Q2 results FY27 comparison.

What are the main Mangalam Drugs Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The Mangalam Drugs Q2 results expectations centre on revenue against the Rs 49.54 crore base, net profit against a loss of Rs 7.35 crore, operating margin against 1.59% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is Mangalam Drugs and Organics share price today ahead of the Q2 earnings?

Ans. Mangalam Drugs and Organics share price is Rs 34.00 on the NSE as of 11 September 2026, up 1.22% from Rs 33.59. The stock is about 35.1% below its 52-week high of Rs 52.40 and 30.5% above its 52-week low of Rs 26.05, at a market capitalisation of Rs 54 crore.

Is Mangalam Drugs and Organics a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on Mangalam Drugs and Organics Ltd. The stock trades at a price-to-book ratio of 0.52 with a return on equity of -35.2%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.